The companies will advance two clinical trials of trametinib plus naporafenib for RAS Q61X solid tumours and NRAS-mutant melanoma. Credit: Chinnapong / Shutterstock.

Erasca has entered two clinical trial collaboration and supply agreements with Novartis to support the development of mitogen-activated protein kinase kinase (MEK) inhibitor trametinib in combination with naporafenib for cancer.

The trials, SEACRAFT-1 and SEACRAFT-2, aim to treat patients with rat sarcoma (RAS) Q61X solid tumours and previously treated NRAS-mutant melanoma, respectively.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

SEACRAFT-1 is a Phase Ib trial which will assess the combination of naporafenib and trametinib in patients with RAS Q61X solid tumours.

The Phase III randomised SEACRAFT-2 trial is enrolling subjects with NRAS-mutant unresectable or metastatic melanoma.

The studies are sponsored by Erasca while Novartis will provide trametinib at no cost for the trial.

See Also:

Naporafenib is a pan-RAF inhibitor, which demonstrated potential as both a first-in-class and best-in-class treatment option.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It has been dosed in more than 500 patients so far, demonstrating tolerability, safety, and pharmacokinetic and pharmacodynamic profiles as a single agent and combination therapy.

Clinical proof-of-concept (PoC) was proven for use along with trametinib for neuroblastoma rat sarcoma (NRAS)-mutant melanoma, including NRAS Q61X melanoma.

Preliminary clinical PoC has also been established for the combination regimen in non-small cell lung cancer.

Erasca’s immediate focus is on advancing naporafenib plus trametinib through regulatory approval processes for NRAS-mutant melanoma in the SEACRAFT-2 trial and for RAS Q61X tissue agnostic solid tumours in the SEACRAFT-1 trial.

Furthermore, the company is investigating additional combinations with other therapeutic agents in its pipeline.

Erasca chairman, CEO and co-founder Jonathan Lim said: “We are excited to work with Novartis to further evaluate the promising clinical development of naporafenib in combination with trametinib in our SEACRAFT trials as part of our two lead indications: NRASm melanoma and RAS Q61X solid tumours.

“Both trials are supported by compelling anti-tumour activity with a tolerable and manageable adverse event profile demonstrated in clinical data generated by Novartis. We expect to initiate our SEACRAFT-2 Phase III trial in the first half of 2024 and report initial SEACRAFT-1 Phase Ib combination data in RAS Q61X solid tumours between the second and fourth quarters of 2024.”